Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has been given an average rating of “Hold” by the ten analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $10.83.
TTPH has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. SunTrust Banks reissued a “buy” rating and set a $10.00 target price on shares of Tetraphase Pharmaceuticals in a report on Wednesday, February 14th. Stifel Nicolaus reduced their target price on Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, February 14th. B. Riley initiated coverage on Tetraphase Pharmaceuticals in a report on Monday, February 12th. They set a “buy” rating and a $11.00 target price for the company. Finally, Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 28th.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,167 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total transaction of $44,507.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director L Patrick Gage bought 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction on Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the acquisition, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of TTPH. Schwab Charles Investment Management Inc. increased its holdings in shares of Tetraphase Pharmaceuticals by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 874 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Tetraphase Pharmaceuticals by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 194,144 shares of the biopharmaceutical company’s stock valued at $1,384,000 after purchasing an additional 6,247 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Tetraphase Pharmaceuticals by 6.9% in the second quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 3,800 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $162,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $205,000. 56.34% of the stock is owned by hedge funds and other institutional investors.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.08 during mid-day trading on Monday, reaching $2.12. The company’s stock had a trading volume of 1,905,435 shares, compared to its average volume of 1,103,591. The stock has a market capitalization of $109.38, a P/E ratio of -0.74 and a beta of 2.29. Tetraphase Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $9.93.
TRADEMARK VIOLATION WARNING: “Tetraphase Pharmaceuticals Inc (TTPH) Receives $17.00 Average Price Target from Analysts” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/19/tetraphase-pharmaceuticals-inc-ttph-receives-17-00-average-price-target-from-analysts.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.